Ignite Creation Date:
2025-12-24 @ 4:36 PM
Ignite Modification Date:
2026-02-17 @ 10:33 PM
Study NCT ID:
NCT03108066
Status:
COMPLETED
Last Update Posted:
2024-09-24
First Post:
2017-03-28
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003)
Sponsor:
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | VHL Gene Mutation | View |
| None | VHL | View |
| None | VHL Syndrome | View |
| None | VHL Gene Inactivation | View |
| None | Von Hippel | View |
| None | Von Hippel-Lindau Disease | View |
| None | Von Hippel's Disease | View |
| None | Von Hippel-Lindau Syndrome, Modifiers of | View |
| None | Clear Cell Renal Cell Carcinoma | View |
| None | Clear Cell RCC | View |
| None | ccRCC | View |
Keywords: